Cover Image
市場調查報告書

全身性紅斑性狼瘡市場:治療(抗瘧疾藥,非類固醇抗發炎性藥,皮質類固醇細胞毒性免疫抑製藥,生技藥品,小分子),地區別預測

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region - Forecast (2016-2021)

出版商 IndustryARC 商品編碼 422599
出版日期 內容資訊 英文 136 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全身性紅斑性狼瘡市場:治療(抗瘧疾藥,非類固醇抗發炎性藥,皮質類固醇細胞毒性免疫抑製藥,生技藥品,小分子),地區別預測 Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region - Forecast (2016-2021)
出版日期: 2016年09月22日 內容資訊: 英文 136 Pages
簡介

本報告提供全球全身性紅斑性狼瘡市場相關調查,彙整市場趨勢與策略性分析,不同治療,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 全身性紅斑性狼瘡市場:概要

第2章 摘要整理

第3章 市場環境

  • 市場佔有率分析
  • 競爭分析
  • 產品基準
  • 終端用戶分析
  • 前五名公司的財務分析

第4章 市場力量

  • 促進要素
  • 阻礙要素
  • 機會
  • 課題
  • 波特五力分析

第5章 策略性分析

  • 價值鏈分析
  • 價格分析
  • 機會分析
  • 產品/市場生命週期分析
  • 供給者和經銷商

第6章 不同治療

  • 抗瘧疾藥
  • 非類固醇抗發炎性藥
  • 皮質類固醇細胞毒性·免疫抑製藥
  • 生技藥品
  • 小分子

第7章 各地區市場

  • 歐洲
  • 亞太地區
  • 北美
  • 其他

第8章 市場熵

  • 擴大
  • 技術發展
  • 合併·收購,合資企業
  • 供給 - 契約

第9章 企業簡介

第10章 附錄

目錄

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, joint pain, and temporary loss of cognitive ability. Immune response is directed toward the body's own cells, resulting in acute or chronic inflammation. Symptoms of lupus are general and hence often mistaken with symptoms of other diseases. This results in unnoticed progression of disease in the body. The disease is more common in women and usually affects individuals in the age group of 25 to 45. Although the main cause of disease is unknown, it is linked to genetic and hormonal factors. Globally increasing awareness about lupus is expected to remain key growth driver during the period of study.

Geographically, North America dominates the systemic lupus erythematosus market driven by best in class infrastructure, easy access to healthcare, higher awareness about the disease amongst citizens as well as practitioners, and higher spending by the citizens towards healthcare expenditure. North America was followed by Europe and Asia-Pacific as second and third largest markets for systemic lupus erythematosus market. Asia Pacific is projected to have fastest growth, owing to rapidly developing medical infrastructure, increasing medical tourism, increased spending, and increasing awareness amongst population in developing nations such as China, and India in this region.

This report identifies the global systemic lupus erythematosus market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the systemic lupus erythematosus market.

This report segments the systemic lupus erythematosus market on the basis of therapies and regional market as follows:

Systemic Lupus Erythematosus Market research report is classified on the basis of therapies. Some of the major therapies covered in this report are as follows: Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the systemic lupus erythematosus market. Some of the major companies' profiles in detail are as follows:

F. Hoffmann-la roche ltd

Glaxosmithkline plc (gsk)

Hadasit medical research services and development

Hansa medical ab

Harbor biosciences

Table of Contents

1. Systemic Lupus Erythematosus Market - Overview

2. Executive Summary

3. Systemic Lupus Erythematosus Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Systemic Lupus Erythematosus Market- Forces

  • 4.1. Drivers
  • 4.2. Increasing awareness about SLE in emerging economies
  • 4.3. Restraints
  • 4.4. Opportunities
  • 4.5. Challenges
  • 4.6. Porter's Five Forces Analysis
    • 4.6.1. Bargaining Power of Suppliers
    • 4.6.2. Bargaining Power of Buyers
    • 4.6.3. Threat of New Entrants
    • 4.6.4. Threat of Substitutes
    • 4.6.5. Degree of Competition

5. Systemic Lupus Erythematosus Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Systemic Lupus Erythematosus Market, By Therapies

  • 6.1. Antimalarial Drugs
  • 6.2. Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
  • 6.3. Corticosteroids Cytotoxic & Immunosuppressive Drugs
  • 6.4. Biologics
  • 6.5. Small Molecules

7. Systemic Lupus Erythematosus Market, By Geography

  • 7.1. Europe
    • 7.1.1. Germany
    • 7.1.2. France
    • 7.1.3. Italy
    • 7.1.4. Spain
    • 7.1.5. Russia
    • 7.1.6. U.K.
    • 7.1.7. Rest of Europe
  • 7.2. Asia Pacific
    • 7.2.1. China
    • 7.2.2. India
    • 7.2.3. Japan
    • 7.2.4. South Korea
    • 7.2.5. Rest of Asia-Pacific
  • 7.3. North America
    • 7.3.1. U.S.
    • 7.3.2. Canada
    • 7.3.3. Mexico
  • 7.4. Rest of the World (RoW)
    • 7.4.1. Brazil
    • 7.4.2. Rest of RoW

8. Systemic Lupus Erythematosus Market - Entropy

  • 8.1. Expansion
  • 8.2. Technological Developments
  • 8.3. Merger & Acquisitions, and Joint Ventures
  • 8.4. Supply- Contract

9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 9.1. Anthera pharmaceuticals inc
  • 9.2. Biotest ag
  • 9.3. Biotica technology ltd.
  • 9.4. Cephalon
  • 9.5. Cornerstone therapeutics inc.
  • 9.6. Creabilis therapeutics s.r.l.
  • 9.7. Dynavax technologies
  • 9.8. Eli lilly
  • 9.9. F. Hoffmann-la roche ltd
  • 9.10. Glaxosmithkline plc (gsk)
  • 9.11. Hadasit medical research services and development
  • 9.12. Hansa medical ab
  • 9.13. Harbor biosciences

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

10. Appendix

  • 10.1. Abbreviations
  • 10.2. Sources
  • 10.3. Research Methodology
  • 10.4. Bibliography
  • 10.5. Compilation of Expert Insights
  • 10.6. Disclaimer
Back to Top